James R. Erickson Ph.D.
Dr. Erickson joined Ferghana in 2013 and is involved in M&A, private placements and corporate partnering in diagnostics, medical devices and therapeutics. Dr. Erickson has held senior management roles at companies including Exactus, point-of-care diagnostic device company, AGY Therapeutics, a neuro-genomics company, and Entelos, a predictive biosimulations company.
In 2005, Dr. Erickson served as CEO of BayPoint Biosystems, a proteomic company focused on commercializing diagnostics and research tools technology from the M.D. Anderson Cancer Center. Under his direction, BayPoint established biomarker discovery and companion diagnostic development alliances with 12 pharmaceutical, biotechnology and life science companies.
Dr. Erickson graduated from the University of California, Berkeley with a degree in biochemistry and received his Ph.D. in genetics from Washington University, St. Louis.